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Abstract
Background: TRAIL/Apo2L is a pro-apoptotic ligand of the TNF family that engages the apoptotic machinery through two
pro-apoptotic receptors, TRAIL-R1 and TRAIL-R2. This cell death program is tightly controlled by two antagonistic receptors,
TRAIL-R3 and TRAIL-R4, both devoid of a functional death domain, an intracellular region of the receptor, required for the
recruitment and the activation of initiator caspases. Upon TRAIL-binding, TRAIL-R4 forms a heteromeric complex with the
agonistic receptor TRAIL-R2 leading to reduced caspase-8 activation and apoptosis.
Methodology/Principal Findings: We provide evidence that TRAIL-R4 can also exhibit, in a ligand independent manner,
signaling properties in the cervical carcinoma cell line HeLa, through Akt. Ectopic expression of TRAIL-R4 in HeLa cells
induced morphological changes, with cell rounding, loss of adherence and markedly enhanced cell proliferation in vitro and
tumor growth in vivo. Disruption of the PI3K/Akt pathway using the pharmacological inhibitor LY294002, siRNA targeting
the p85 regulatory subunit of phosphatidylinositol-3 kinase, or by PTEN over-expression, partially restored TRAIL-mediated
apoptosis in these cells. Moreover, the Akt inhibitor, LY294002, restituted normal cell proliferation index in HeLa cells
expressing TRAIL-R4.
Conclusions/Significance: Altogether, these results indicate that, besides its ability to directly inhibit TRAIL-induced cell
death at the membrane, TRAIL-R4 can also trigger the activation of signaling pathways leading to cell survival and
proliferation in HeLa cells. Our findings raise the possibility that TRAIL-R4 may contribute to cervical carcinogenesis.
Citation: Lalaoui N, Morle ´ A, Me ´rino D, Jacquemin G, Iessi E, et al. (2011) TRAIL-R4 Promotes Tumor Growth and Resistance to Apoptosis in Cervical Carcinoma
HeLa Cells through AKT. PLoS ONE 6(5): e19679. doi:10.1371/journal.pone.0019679
Editor: Frederic Rieux-Laucat, Pavillon Kirmisson, France
Received December 14, 2010; Accepted April 13, 2011; Published May 20, 2011
Copyright:  2011 Lalaoui et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work is supported by grants of the Conseil Regional de Bourgogne, the INCa (Institut National du Cancer) Canceropole Grand-Est, (Agence
Nationale de la Recherche, ANR-06-JCJC-0103 and 07-PCV-0031) and the European Community (ApopTrain Marie Curie RTN). NL, A. Morizot, DM, A. Morle ´ and GJ
are supported by fellowships from the Ligue Nationale contre le Cancer, the Ministry of Research and Education, the ARC (Association pour la Recherches u rl e
Cancer), the INSERM and the Conseil Regional de Bourgogne. EI was supported by a fellowship from the Apoptrain Marie Curie RTN. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: omicheau@u-bourgogne.fr
Introduction
TRAIL/Apo2L is regarded as a promising anticancer agent for
cancer therapy and is currently being evaluated in clinical trials
[1]. TRAIL binds to four membrane-anchored receptors: TRAIL-
R1 (DR4), TRAIL-R2 (DR5, Killer, TRICK), TRAIL-R3 (DcR1,
LIT, TRID) or TRAIL-R4 (DcR2, TRUNDD), and one soluble
receptor, osteoprotegerin (OPG) [1]. TRAIL induces cell death
through its interaction with either TRAIL-R1 or TRAIL-R2.
These two agonistic receptors harbor, within their cytoplasmic
region, a relatively small amino acid stretch called the death
domain (DD), which is necessary and sufficient to transduce the
death signal [2]. Activation of TRAIL-R1 or TRAIL-R2 by
trimeric TRAIL induces the recruitment of the adaptor protein
FADD (Fas-associated death domain protein) via homotypic
interactions with their respective DD, allowing in turn the
recruitment of the initiator caspases, procaspases-8 and -10
[3,4], leading to the formation of the death-inducing signaling
complex (DISC) [5]. Within the DISC, the initiator caspases-8 and
-10 undergo catalytic cleavage inducing their release to the cytosol
and the triggering of the caspase cascade that ultimately leads to
apoptosis. In contrast, TRAIL binding to TRAIL-R3 or TRAIL-
R4 fails to induce the apoptotic machinery because none of these
receptors harbor a functional DD [6]. TRAIL-R3 is anchored to
the membrane via its glycosyl-phosphatidylinositol tail (GPI),
whereas TRAIL-R4 is addressed to the cell surface through a
transmembrane domain but includes a truncated DD that is
unable to recruit the adaptor protein FADD [7].
Expression of TRAIL-R3 or TRAIL-R4 confers resistance to
TRAIL-induced cell death in several tumor cell lines and primary
tumors [8,9,10,11,12,13]. These antagonistic receptors, coined
‘‘decoy receptors’’, were initially proposed to act as competitors to
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19679TRAIL-R1 and TRAIL-R2 for TRAIL binding [14]. However,
we and others have provided evidence that TRAIL-R4 should
rather be considered as a regulatory receptor, because TRAIL-R4
is able to interact with TRAIL-R2 within the TRAIL DISC and to
impair caspase-8 activation [10,12,15]. In this study, we provide
new evidence that TRAIL-R4 exhibits a TRAIL-independent
signaling activity that gives rise to oncogenic-like properties in
HeLa cells, mainly through the activation of Akt.
Results
TRAIL-R4 ectopic expression inHeLa cellsmarkedly changes
cell morphology, cell proliferation and tumor growth
Ectopic TRAIL-R4 expression to physiological levels in HeLa
cells (Figure 1A), as well as in other tumors [15], by use of
retroviral vectors, affords good selective protection against
TRAIL-induced cell death, but not Fas ligand (Figure 1B and
C). Strikingly, HeLa cells expressing TRAIL-R4 (H-TRAIL-R4)
undergo drastic morphological changes including cell rounding
and loss of adherence (Figure 1D). As compared to control cells
(H-Ctl) infected with an empty vector, H-TRAIL-R4 cells
exhibited a higher proliferative index (Figure 1E). This increase
in cell proliferation is however most likely independent of TRAIL
itself, since the recombinant fusion protein Fc-TRAIL-R2 failed to
affect proliferation in H-TRAIL-R4 cells (Figure S1A). In
agreement with these findings, TRAIL levels were undetectable
in the supernatant or at the surface of H-TRAIL-R4 cells (not
shown). The drastic changes in cell morphology and proliferative
status prompted us to check whether TRAIL-R4 overexpression
confers tumor growth advantage in vivo. Parental (H-Ctl) and
TRAIL-R4 expressing cells (H-TRAIL-R4) were implanted into
nude mice in the left and the right flank, respectively of the same
Figure 1. TRAIL-R4 protects HeLa cells from TRAIL-induced apoptosis and enhances tumor cell growth in vitro and in vivo. (A) HeLa
stably transduced with retroviruses encoding TRAIL-R4 (H-TRAIL-R4), or the empty mock retroviral vector (H-Ctl), were analyzed by flow cytometry for
TRAIL receptor staining as indicated. (B) Cellular viability of the populations was evaluated by PMS/MTS 24 hours after treatment with increasing
concentrations of recombinant His-TRAIL. HeLa control (H-Ctl in open squares) and HeLa expressing TRAIL-R4 (H-TRAIL-R4 in filled circles). Mean
viability % and SD from three independent experiments are shown (mean 6 SD). ***P,0.001, two-way ANOVA with Bonferroni post-tests, H-TRAIL-R4
compared with H-Ctl-Mock. (C) Apoptosis-induced by TRAIL (500 ng/ml) in H-Ctl and H-TRAIL-R4 cells 24 hours after stimulation. Apoptosis was
determined by Hoechst staining. Data are representative of at least three independent experiments. ***P,0.001, student t-test. (D) Representative
light microscopic picture of H-Ctl versus H-TRAIL-R4 treated or not (NT) with 500 ng/ml TRAIL for 16 hours. (E) Cell proliferative index was followed
for 4 days and measured using CFSE by flow cytometry. Mean analysis from three independent experiments is shown. HeLa control (H-Ctl in open
squares) and HeLa expressing TRAIL-R4 (H-TRAIL-R4 in filled circles). (F) Time dependent growth of HeLa control (H-Ctl in open squares) and HeLa
expressing TRAIL-R4 (H-TRAIL-R4 in filled circles) in nude mice after xenograft (n=10). These results represent the mean tumor volume in arbitrary
units 6 SD of a representative experiment performed with six to seven mice per group. (E) and (F) *P,0.05 and ***P,0.001, two-way ANOVA with
Bonferroni post-tests, H-TRAIL-R4 compared with H-Ctl-Mock.
doi:10.1371/journal.pone.0019679.g001
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(Figure 1F). Remarkably, TRAIL-R4 expressing HeLa cells
exhibited a clear tumor growth advantage as compared to control
cells in nude mice.
We next checked whether TRAIL-R4 ectopic expression
affected cell proliferation in two other TRAIL-sensitive tumor
cell lines, the Jurkat T cell lymphoma and the colon carcinoma
SW480. To address this question, Jurkat and SW480 cell lines
were infected with an empty vector (J-Ctl and SW-Ctl) or a
retroviral vector encoding TRAIL-R4 (J-TRAIL-R4 and SW-
TRAIL-R4). Expression levels of TRAIL-R4 and TRAIL-R2 were
analyzed by flow cytometry (Figure 2A and B) and cell sensitivity
to TRAIL-induced cell death was determined by PMS-MTS
assay. Similar to HeLa cells, ectopic expression of TRAIL-R4 in
Jurkat or SW480 cells inhibited TRAIL-induced cell death in a
dose-dependent manner (Figure 2C and D). TRAIL-R4 expres-
sion, however, induced no particular modification of cell
proliferation as compared to control cells (Figure 2E and F), and
no change in cell morphology could be observed (not shown).
TRAIL-R4-mediated constitutive Akt activation in HeLa
cells contributes to cell resistance to TRAIL-induced
apoptosis and to increased cell proliferation
To explore the molecular basis of the deregulated death
commitment and proliferation potential in HeLa cells express-
ing TRAIL-R4 ectopically, we next analyzed the activation
status of Akt, a survival pathway that plays a central role in
diverse cellular functions, including survival, growth, and
proliferation [16].
Strikingly, while Akt appeared to be constitutively activated in
Jurkat and SW480 cells irrespective of TRAIL-R4 ectopic
expression, a differential Akt phosphorylation profile was detected
in H-TRAIL-R4 cells as compared to control parental HeLa cells
(Figure3A).Constitutive activationofAkt in HeLacellswas TRAIL-
independent as TRAIL stimulation only marginally induced Akt
phosphorylation in H-Ctl cells (Figure 3B). Activation of Akt in these
cells appeared to be restricted to TRAIL-R4. Accordingly, ectopic
expression of TRAIL-R3 (Figure 3B), TRAIL-R2 (not shown) or a
chimeric TRAIL receptor encoding the extracellular domain of
Figure 2. TRAIL-R4 ectopic expression fails to promote cell proliferation in Jurkat and SW480 cells. (A and B) Jurkat and SW480 cells
were stably transduced with retroviruses encoding TRAIL-R4 (J-TRAIL-R4 and SW-TRAIL-R4), or the empty mock retroviral vector (J-Ctl and SW-Ctl),
respectively. Cells were analyzed by flow cytometry for TRAIL receptor staining as indicated. (C and D) Cellular viability was evaluated by PMS/MTS
24 hours after treatment with increasing concentrations of recombinant His-TRAIL. Jurkat or SW480 control cells (J-Ctl or SW-Ctl in open squares) and
Jurkat or SW480 expressing ectopically TRAIL-R4 (J-TRAIL-R4 or SW-TRAIL-R4 in filled circles). (E and F) Cell proliferative index was measured as in
Figure 1. Mean proliferative index, viable cells and SD from three independent experiments are shown (mean 6 SD). *P,0.05, **P,0.01 and
***P,0.001, two-way ANOVA with Bonferroni post-tests, J- or SW-TRAIL-R4 compared with J- and SW-Ctl-Mock respectively.
doi:10.1371/journal.pone.0019679.g002
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Akt activation, contrary to a chimeric construct encoding TRAIL-
R4 intracellular domain (Figure S2). Inhibition of Akt phosphory-
lation either using siRNA targeting the regulatory subunit of PI3K
(Figure 3C), or by over-expressing PTEN (Figure 3D) sensitized H-
TRAIL-R4 cells to TRAIL-induced cell death, indicating that cell
resistance to TRAIL in these cells is, at least partly, due to the
sustained activation of the Akt pathway. Accordingly, the pharma-
cological inhibitor of Akt phosphorylation, LY294002, significantly
restored TRAIL-induced apoptosis in H-TRAIL-R4 cells
(Figure 4A). Notably, sensitization to TRAIL-induced cell death
was not associated with an increase in caspase-8 cleavage, but rather
with an increase in caspase-3 processing (Figure 4B and C),
suggesting that Akt-mediated inhibition most likely occurs down-
stream of the TRAIL DISC probably at the mitochondrial or post
mitochondrial level. Remarkably, LY294002 reduced H-TRAIL-
R4-mediated cell proliferation to levels comparable to those of
control parental cells (Figure 4D).
Altogether our findings suggest that TRAIL-R4 in HeLa cells is
a regulatory receptor whose anti-apoptotic functions involve both
TRAIL DISC targeting and activation of the Akt survival
pathway.
Figure 3. TRAIL-R4-mediated constitutive Akt activation contributes to cell resistance to TRAIL-induced apoptosis in HeLa cells. (A)
Total Akt and phospho-Akt were monitored by western blot from HeLa, Jurkat and SW480 cells expressing TRAIL-R4 and compared to control cells
(Ctl). Unstimulated or TRAIL stimulated (500 ng/ml for 30 minutes) cell samples are shown. (B) H-Ctl, H-TRAIL-R4 or HeLa cells expressing TRAIL-R3 (H-
TRAIL-R3) were stimulated with TRAIL (500 ng/ml) for the indicated time and total Akt or phospho-Akt expression was assessed as above. Sample
loading was assessed using GAPDH for normalization. (C) H-Ctl and H-TRAIL-R4 cells were transfected with a siRNA targeting PI3K or a scramble siRNA
for 48 hours and stimulated or not with TRAIL (500 ng/ml) for 6 hours. Phosphorylation of Akt and PI3K expression levels were analyzed by western
blot, and apoptosis was analyzed by Hoechst staining. (D) H-Ctl and H-TRAIL-R4 cells were transfected with a GFP mock vector or with a vector
encoding PTEN for 24 hours. Expression levels of phospho-Akt and PTEN were analyzed by western blot and apoptosis induced by TRAIL was
monitored as above. **P,0.01 and ***P,0.001, one-way ANOVA with Bonferroni’s multiple comparison test.
doi:10.1371/journal.pone.0019679.g003
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TRAIL is an attractive anti-tumoral agent owing to its ability to
selectively induce apoptosis in tumor cells [17,18] and thus TRAIL
derivatives or recombinant TRAIL preparations have entered clinical
trials [1]. The molecular mechanisms governing TRAIL-induced cell
death or signal transduction remain, however, only partially
understood. Cell resistance to TRAIL-induced cell death can arise
Figure 4. Inactivation of Akt restores partial sensitivity to TRAIL-induced cell death in TRAIL-R4 expressing cells and restores
normal cell proliferation index. (A) HeLa H-Ctl and H-TRAIL-R4 cells were left untreated or pretreated for 1 hour with the Akt inhibitor LY294002
(100 mM) then stimulated or not with TRAIL (500 ng/ml) for 24 hours and apoptosis was analyzed after Hoechst staining. These results are
representative of at least 3 independent experiments. Mean percentage of apoptotic cells and SD are shown (mean 6 SD). ***P,0.001, one-way
ANOVA with Bonferroni’s multiple comparison test. (B) Cells were stimulated either with LY294002 (100 mM) then treated or not with TRAIL as above
and cell lysates were processed by western blot for the analysis of Akt phosphorylation, caspase-8 and active caspase-3. Filled arrows show caspase
cleavage products. The empty arrow shows full length caspase-8. Densitometry analysis of caspase-3 p17 and caspase-8 full-length immunoreactive
bands were obtained using ImageJ software, normalized with respect to GAPDH, and plotted in (C). (D) Cellular growth in the presence or the
absence of Akt inhibitor LY294002 (10 mM) was monitored during 4 days by flow cytometry analysis using CFSE. LY294002 was applied every day to
the cell culture supernatant to afford sustained inhibition of Akt.
doi:10.1371/journal.pone.0019679.g004
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specifically from the deregulation of the expression and/or the
functionality of TRAIL receptors. Likewise, loss of TRAIL-R1 or
TRAIL-R2 expression [19,20,21,22] or expression of TRAIL-R3 or
TRAIL-R4, two main antagonistic receptors [9,10,11,12,13], abrogate
TRAIL-induced cell death selectively, without affecting the apoptotic
machinery triggered by other members of the TNF family, nor the
intrinsic pathway. Likewise, overexpression of TRAIL-R4 protects
tumor cells against TRAIL-induced cell death by regulating caspase-8
activation at the DISC level [10,15].
In the present study, we provide evidence that TRAIL-R4 in
HeLa cells a) partially protects from TRAIL-induced apoptosis
and b) enhances cell proliferation index through Akt activation in
a TRAIL-independent manner. Remarkably, TRAIL-R4-mediat-
ed Akt activation in HeLa cells leads to drastic morphological
changes, such as reduced cell size and loss of adhesion, suggesting
that TRAIL-R4 may exhibit pro-metastatic properties (Figure 5).
These findings, however, may be restricted to tumor cell lines
expressing low levels of active Akt, since contrary to HeLa cells, no
morphological or proliferative changes were detected in Jurkat and
SW480 cells, which express high levels of active Akt. Our findings
nonetheless clearly suggest, for the first time, that TRAIL-R4
exhibits unexpected signaling properties conferring cellular growth
advantage both in vitro and in vivo.
Besides apoptosis triggering, and depending on the cellline or type,
TRAIL stimulation can induce non apoptotic signaling pathways
including Akt [23,24,25,26], NF-kB [27] or MAPK [28,29], cell
proliferation [26,30,31] or differentiation [32,33,34]. It has recently
been proposed that the activation of non apoptotic signaling
pathways by TRAIL involve the formation of a cytosolic secondary
complex which, contrary to TNF [35], allows the recruitment of
adaptor proteins and kinases including TRAF2, RIP or NEMO [36].
Activation of Akt by TRAIL-R4 in HeLa cells by such a secondary
complex is unlikely, as this pathway appears to be activated in a
TRAIL-ligand independent manner. Moreover, we have not yet
been able to identify this secondary complex (not shown).
How TRAIL-R4 mediates Akt activation in HeLa cells remains
unknown for the moment. TRAIL-R4 shares relatively high
homology with TRAIL-R1 and TRAIL-R2 [7] and is the only
TRAIL antagonistic receptor that harbors an intracellular
domain. Interestingly, ectopic expression of the TRAIL-R4
intracellular domain in HeLa cells induces constitutive AKT
activation. This domain would therefore provide an ideal docking
site for a putative binding partner. It is therefore tempting to
speculate that the intracellular domain of TRAIL-R4 may interact
with membrane associated or cytosolic proteins already known to
bind to TRAIL-R1 or TRAIL-R2 such as GSK3 [37], ARAP1
[38], DAP3 [39], Burton’s tyrosine kinase [40], or PRTM5 [41].
The exact molecular mechanism involved in this regulation
therefore needs to be further investigated.
Altogether, our findings indicate for the first time that, besides
inhibiting TRAIL-induced cell death, TRAIL-R4 is able to regulate
the PI3K/Akt signaling pathway in cell type-dependent manner
leading to cell resistance to apoptosis and to enhanced cellular growth.
Materials and Methods
Reagents and antibodies
His-tagged recombinant soluble human TRAIL and Fc-TRAIL-R2
were produced and used as described previously [42]. For Western
blotting experiments, anti-GAPD H ,a n t i - P I 3 K ,a n t i - H S C 7 0w e r e
obtained from Santa Cruz Biotechnology (CA, USA), anti-phospho-
Akt from Upstate (Milipore, Molsheim, France), anti-Akt, and anti-
PTEN from Cell Signaling (Ozyme, Saint Quentin Yvelines, France).
Antibodies used for flow cytometry, anti-TRAIL-R1 (wB-K32), anti-
TRAIL-R2 (B-L27), anti-TRAIL-R3 (wB-B44), anti-TRAIL-R4 (wB-
P30), and anti-TRAIL were from Diaclone (Besanc ¸on, France). The
PI3K/AKt inhibitor LY294002 was purchased from Cell Signaling
(Ozyme, Saint Quentin Yvelines, France).
Cell culture and transfection
HeLa (human cervix carcinoma), SW480 (Colon carcinoma) and
Jurkat cells (T Lymphoma) were obtained from the ATCC. HeLa
and SW480 cells were cultured in high-glucose Dulbecco’s modified
Eagle’s medium (Sigma-Aldrich, Lyon, France) supplemented with
10% fetal calf serum (Gibco-BRL, Erigny, France), and Jurkat cells
were cultured in RMPI as above. Transfection of HeLa cells was
carried out using JetsiENDO
TM reagent (Eurogentec, Angers,
France), according to the manufacturer’s instructions using the
following PI3K siRNA (59-GGGUGUGGAUUACACCAUU-39)
and siRNA control (Invitrogen, Cergy Pontoise, France). PTEN
transfections were performed with the pSG5L-HA-PTEN construct
(kindly provided by Dr William Sellers, Dana-Farber Cancer
Institute, Boston) using TransPEI
TM (Eurogentec).
Retroviral production and cell transduction
The retroviral vector pMSCVpuro and the generation of viruses
have previously been described (30). TRAIL-R4 full-length construct
Figure 5. Model for Akt activation from TRAIL-R4 in HeLa cells.
TRAIL-R4 is known to inhibit caspase-8 activation induced by TRAIL-R2
upon TRAIL stimulation. We propose here that TRAIL-R4 may, in
addition, trigger Akt activation in a ligand independent manner.
Constitutive activation of Akt in HeLa cells would therefore inhibit
caspase-3 activation at the mitochondrial or post-mitochondrial level to
inhibit apoptosis induced by TRAIL, and could possibly foster cell
proliferation.
doi:10.1371/journal.pone.0019679.g005
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vector pMSCV-puro as a HindII-XhoI fragment. HeLa cells were
transduced for 16 hours with viral supernatants containing polybrene
(8 mg/ml), washed in phosphate buffered saline (PBS), and selected in
complete medium containing puromycin (2.5 mg/ml).
Measurement of cell viability and apoptosis
Cellviabilityassayswere performedin96-wellplates.10
4cellsper
well were incubated at 37uC for 24 hours with increasing
concentrations of His-TRAIL (from 0 to 10,000 ng/ml). Cell
viability was determined by the PMS/MTS method, according to
the manufacturer’s specifications (Promega, Madison, WI, USA.).
Apoptosis was assessed by Hoechst staining by determining the
percentage of condensed nucleifrom at least 300 cells percondition.
For Akt inhibition, cells were pretreated with LY294002 (100 mM)
one hour before TRAIL treatment (500 ng/ml, 5 hours). PI3K
inhibition and PTEN expression were measured 48 and 24 hours
hours after transfection respectively and cells were simultaneously
treated 5 hours with 500 ng/ml of His-TRAIL.
Cell proliferation
To measure cell proliferation the different cellular populations
were plated at the same density and counted each day.
CellTrace
TM CFSE Cell Proliferation Kit (Molecular Probes,
Invitrogen) was used to measure cell proliferation using a LSRII
flow cytometer (DB Biosciences) and the ModFIT Software (Verity
Software House Topsham, ME) was applied to determine the
proliferation index.
Western blotting
Lysates were resolved by sodium dodecyl sulfate- polyacryl-
amide gel electrophoresis and transferred to nitrocellulose
membranes. Nonspecific binding sites were blocked in PBS
containing 0.05% Tween 20 and 5% powdered milk. Immuno-
blots were then incubated with specific primary antibody, followed
by horseradish peroxidase-conjugated secondary antibody, and
developed by the enhanced chemiluminescence method according
to the manufacturer’s protocol (Pierce, Rockford, IL).
In vivo studies
Six weeks old female athymic nude mice (Harlan, Le Malcourle,
Gannat) were subcutaneously xenografted with 1610
6 H-Ctl in the
right flank and 1610
6 H-TRAIL-R4 in the left flank (n=10). Tumor
volume was obtained after caliper measurement of the tumor and the
formula (l6l6L)/2 with l the smaller and L the higher dimension.
Supporting Information
Figure S1 (A) The proliferative index of H-Ctl and H-TRAIL-
R4 cells was measured in the presence or in the absence of 10 mg
recombinant Fc-TRAIL-R2, as described in the manuscript
Figure 1E. Fc-TRAIL-R2 was added to the culture daily for 4
days. (B) Representative picture of nude mice xenografted with
HeLa control (H-Ctl on the left flank) and HeLa expressing
TRAIL-R4 (H-TRAIL-R4 on the right flank) and the corre-
sponding tumors harvested from mice pictured.
(TIFF)
Figure S2 (A) Schematic representation of TRAIL receptor
chimeric constructs (OM043, OM050 and OM051). Vectors
were constructed using standard cloning procedures. TRAIL-R2
and TRAIL-R4 intracellular domains (icd) were obtained by
polymerase chain reaction from pCRIII vectors encoding full
length TRAIL-R2 and TRAIL-R4 as described earlier [10], with
the following primer pairs: TRAIL-R2 forward primer (59- GTC
GAC TGT TCT CTC TCA GGC ATC-39); reverse primer (59-
CTC GAG CGG CCG CCA GTG TGA TGG-39) and TRAIL-
R4 forward primer (59- GTC GAC TAT CAC TAC CTT ATC
ATC -39); reverse primer (59- CTC GAG TCA CAG GCA GGA
CGT AGC -39) containing a SalI and a XhoI site. Oligonucle-
otide primers and Pfu polymerase were purchased from Euro-
gentech (Angers, France) and Sigma-Aldrich (Lyon, France)
respectively. The resulting amplified fragments were subcloned
into pCR-Blunt (Invitrogen, Cergy Pontoise, France) and checked
by sequencing. TRAIL-R2-icd and TRAIL-R4-icd were sub-
cloned between the SalI and XhoI sites of pCRIII vectors
encoding the extracellular domains (ecd) of TRAIL-R1 (aa 1–
239, PS688), TRAIL-R2 (aa 1–212, PS664) or TRAIL-R4 (aa1–
211, PS690), kindly provided by Dr Pascal Schneider (Lausanne,
Switzerland). Resulting TRAIL-R1ecd-TRAIL-R2icd, TRAIL-
R4ecd-TRAIL-R2icd and TRAIL-R2ecd-TRAIL-R4icd DNA
fragments were subcloned into a pMSCV-Puro retroviral vector
between HindIII and XhoI, generating pMSCV-Puro-TRAIL-
R1ecd-TRAIL-R2icd (OM043), pMSCV-Puro-TRAIL-R4ecd-
TRAIL-R2icd (OM051) and pMSCV-Puro-TRAIL-R2ecd-
TRAIL-R4icd (OM050). (B) Receptor expression in HeLa cells
was analyzed by flow cytometry after infection of TRAIL
receptor fusion constructs (OM043, OM050 and OM051) or
the corresponding empty vector (OM181). (C) Biochemical
analysis of TRAIL chimeric receptors. Immunoprecipitations
were performed using a control antibody (lanes 1, 4, 7, 10, 13 and
16) or antibodies targeting TRAIL-R1 (lanes 2, 3, 5 and 6),
TRAIL-R2 (lanes 8, 9, 11 and 12) and TRAIL-R4 (lanes 14, 15,
17 and 18) from DIACLONE (Besanc ¸on, France). Antibodies
were applied either after lysis (1, 3, 4, 6, 7, 9, 10, 12, 13, 15, 16
and 18), or on intact cells (2, 5, 8, 11, 14 and 17) for 1 h on ice.
The latter samples were subsequently subjected to lysis in NP40
lysis buffer and samples were precleared on sepharose 6B beads
before immunoprecipitation using agarose protein G beads.
Samples were then washed extensively and subjected to western
blot using anti-TRAIL-R1, -R2 and -R4 antibodies from
Milipore (Molsheim, France). Note that TRAIL-R4’s extracellu-
lar domain is not recognized by the anti-TRAIL-R4 antibody
from Chemicon. *ns stands for non specific. (D) AKT activation
was analyzed by western blot as described in the text.
(TIFF)
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